SCHEMBL990709

SCHEMBL990709

O=[N+]([O-])c1ccccc1-n1ccnc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRIA1 P42261 2/20 0.54
GRIA2 P42262 2/20 0.54
GRIA3 P42263 2/20 0.54
GRIA4 P48058 2/20 0.54
GRIK1 P39086 1/20 0.54
GRIK2 Q13002 1/20 0.54
GRIK3 Q13003 1/20 0.54
GRIK4 Q16099 1/20 0.54
GRIK5 Q16478 1/20 0.54
IDO1 P14902 1/20 0.53
CYP3A4 P08684 3/20 0.49
MAPT P10636 3/20 0.49
CYP1A2 P05177 2/20 0.49
CYP2D6 P10635 2/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 2/20 0.49
ALDH1A1 P00352 2/20 0.49
MEN1 O00255 2/20 0.49
KMT2A Q03164 2/20 0.49
LMNA P02545 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9555764 0.86 GRIA1 (0.50) GRIA1GRIA2GRIA3GRIA4GRIK1
SCHEMBL9425651 0.82 GRIA1 (0.52) GRIA1GRIA2GRIA3GRIA4GRIK1
SCHEMBL11700953 0.81 GRIA1 (0.43) GRIA1GRIA2GRIA3GRIA4GRIK1
SCHEMBL11534480 0.80 KMT2A (0.58) IDO1CYP3A4MAPTALDH1A1MEN1
SCHEMBL10786918 0.80 GRIK1 (0.57) GRIA1GRIA2GRIA3GRIA4GRIK1
SCHEMBL10550799 0.79 HCAR1 (0.47) MAPTALDH1A1MEN1KMT2AMAPK1
SCHEMBL7979916 0.78 GRIK1 (0.56) GRIA1GRIA2GRIA3GRIA4GRIK1
SCHEMBL17599033 0.78 GRIA1 (0.56) GRIA1GRIA2GRIA3GRIA4GRIK1
SCHEMBL995544 0.78 GRIK1 (0.56) GRIA1GRIA2GRIA3GRIA4GRIK1
SCHEMBL29758064 0.78 GRIK1 (0.56) GRIA1GRIA2GRIA3GRIA4GRIK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101910175-A N-phenylimidazo [1,2-a ] pyridine-2-carboxamide compounds, preparation and therapeutic use thereof SANOFI AVENTIS 2010-12-08 CN claimed
WO-1999009845-A1 IMIDAZOQUINOXALINE PROTEIN TYROSINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 1999-03-04 WO claimed
US-20240327444-A1 Method for Purifying Nucleotides, Device for Purifying Nucleotides, Hy-Drophobic Reagent, and Hydrophobic Substrate JAPAN SCIENCE AND TECHNOLOGY AGENCY (JP) 2024-10-03 US disclosed
EP-4368628-A1 METHOD FOR PURIFYING NUCLEOTIDES, DEVICE FOR PURIFYING NUCLEOTIDES, HYDROPHOBIC REAGENT, AND HYDROPHOBIC SUBSTRATE Japan Science and Technology Agency (JP) 2024-05-15 EP disclosed
CN-117858885-A Method and device for purifying nucleotide, and hydrophobic reagent and hydrophobic substrate 国立研究开发法人科学技术振兴机构 2024-04-09 CN disclosed
US-11916197-B2 Electrolyte additives for secondary battery, non-aqueous electrolyte for secondary battery comprising same and secondary battery LG ENERGY SOLUTION, LTD. (KR) 2024-02-27 US disclosed
WO-2023282245-A1 METHOD FOR PURIFYING NUCLEOTIDES, DEVICE FOR PURIFYING NUCLEOTIDES, HYDROPHOBIC REAGENT, AND HYDROPHOBIC SUBSTRATE 国立研究開発法人科学技術振興機構 2023-01-12 WO disclosed
US-10910634-B2 Electroactive ionic liquids and surface-modified substrates containing them UNIVERSITÉ PARIS CITÉ (FR) 2021-02-02 US disclosed
EP-3453038-B1 ELECTROACTIVE IONIC LIQUIDS AND SURFACE-MODIFIED SUBSTRATES CONTAINING THEM CENTRE NAT RECH SCIENT (FR) 2020-12-16 EP disclosed
US-20190173078-A1 Electroactive Ionic Liquids And Surface-Modified Substrates Containing Them CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2019-06-06 US disclosed
EP-3453038-A1 ELECTROACTIVE IONIC LIQUIDS AND SURFACE-MODIFIED SUBSTRATES CONTAINING THEM Centre National de la Recherche Scientifique CNRS (FR) 2019-03-13 EP disclosed
WO-1994022865-A1 IMIDAZOLOQUINOXALINONE DERIVATIVES AS EAA ANTAGONISTS BASF AKTIENGESELLSCHAFT (DE) 1994-10-13 WO disclosed
EP-0365907-A1 Process for the preparation of p-nitrophenyl imidazoles BASF Aktiengesellschaft (DE) 1990-05-02 EP disclosed
US-4514214-A Herbicidal sulfamates E. I. DU PONT DE NEMOURS AND COMPANY (US) 1985-04-30 US disclosed
US-4475944-A PLANT GROWTH REGULATORS E. I. DU PONT DE NEMOURS AND COMPANY (US) 1984-10-09 US disclosed
EP-0003560-B1 IMIDAZOLE DERIVATIVES AND SALTS THEREOF, THEIR SYNTHESIS, AND PHARMACEUTICAL FORMULATIONS THE WELLCOME FOUNDATION LIMITED (GB) 1984-05-02 EP disclosed
US-4431815-A CARDIOTONIC AND ANTISHOCK AGENTS; ANTICOAGULANTS BURROUGHS WELLCOME CO. (US) 1984-02-14 US disclosed
EP-0096593-A2 Herbicidal sulfamates E.I. DU PONT DE NEMOURS AND COMPANY (US) 1983-12-21 EP disclosed
EP-0003560-A2 Imidazole derivatives and salts thereof, their synthesis, and pharmaceutical formulations THE WELLCOME FOUNDATION LIMITED (GB) 1979-08-22 EP disclosed
US-4006243-A FUNGICIDE, BACTERICIDE, YEAST SCHERING AKTIENGESELLSCHAFT (DT) 1977-02-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11916197-B2 Electrolyte additives for secondary battery, non-aqueous electrolyte for secondary battery comprising same and secondary battery SCO2, RER1, LPO GRIA1 485/4885GRIA2 812/4885GRIA3 988/4885
US-20240327444-A1 Method for Purifying Nucleotides, Device for Purifying Nucleotides, Hy-Drophobic Reagent, and Hydrophobic Substrate NUDT1, SAMHD1, PNP GRIA1 4001/4885GRIA2 4398/4885GRIA3 4517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.